Headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a news impact score of 0.31 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 100 out of 100, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- Conatus Pharmaceuticals (CNAT) Gains FDA Orphan Drug Designation for IDN-7314 – StreetInsider.com (streetinsider.com)
- FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC (finance.yahoo.com)
- Dermira, Inc. (DERM) has a value of $31.55 per share While Conatus Pharmaceuticals Inc. (CNAT) is stand at $5.10 – Stocks Gallery (stocksgallery.com)
- Conatus Pharmaceuticals Inc. (CNAT) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Time to Buy Conatus Pharmaceuticals Inc (CNAT) After Today’s Significant Decline? – KL Daily (kldaily.com)
Several research analysts have recently issued reports on the stock. Aegis restated a “buy” rating and set a $11.00 price objective on shares of Conatus Pharmaceuticals in a report on Friday, May 5th. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 24th. Stifel Nicolaus restated a “buy” rating and set a $9.00 price objective (up previously from $7.00) on shares of Conatus Pharmaceuticals in a report on Thursday, March 16th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 14th. Finally, FBR & Co restated an “outperform” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a report on Wednesday, March 15th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Conatus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $13.25.
Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at 5.10 on Monday. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $9.40. The stock’s 50 day moving average is $5.66 and its 200 day moving average is $5.14. The firm’s market capitalization is $133.46 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.20. The business had revenue of $7 million for the quarter, compared to the consensus estimate of $5.88 million. During the same period in the prior year, the business posted ($0.35) earnings per share. Equities research analysts forecast that Conatus Pharmaceuticals will post ($0.70) earnings per share for the current fiscal year.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.